London, UK – Researchers are issuing warnings about the dangers of xylazine, a potent animal tranquilizer that has been linked to skin ulcers, overdoses, and multiple deaths since 2022. The substance has been increasingly found in cannabis vapes and illicit sedatives, putting individuals seeking relief from pain, anxiety, and insomnia at risk of unintended consumption.
Studies conducted by King’s College London reveal a concerning trend of xylazine’s prevalence in the UK, with its presence becoming more prominent since the identification of the first fatality in 2022. Unlike in the US, where xylazine is often mixed with potent opioids like heroin or fentanyl, in the UK, the substance has been discovered in counterfeit prescription drugs and vapes containing THC, the psychoactive component of cannabis.
Dr. Caroline Copeland, the senior author of the research, emphasized the alarming implications of this trend, stating that a broader spectrum of drug users beyond heroin users could be exposed to the harms of xylazine. The combination of xylazine with other substances like opioids significantly increases the risk of overdose, posing a growing public health threat in the UK.
The findings, published in the Addiction journal, highlight evidence from toxicology laboratories across the UK, indicating that xylazine was detected in 16 individuals, with 11 resulting in fatalities. In cases where xylazine was implicated in deaths, it was often found in combination with strong opioids, emphasizing the heightened risks associated with its consumption.
Xylazine, a non-opioid sedative and muscle relaxant commonly used in veterinary medicine, poses serious health risks when consumed by humans. The substance can lead to decreased heart and breathing rates, along with the potential to cause severe skin ulcers if injected directly into the bloodstream.
Dr. Copeland recommended proactive measures to prevent an epidemic of xylazine-related incidents, emphasizing the importance of toxicology testing to accurately assess the prevalence of the substance. The emergence of xylazine follows a concerning trend of drug adulteration, with synthetic drugs like nitazenes also contributing to a rise in fatalities among drug users.
In response to the escalating threat posed by xylazine and illicit synthetic drugs, government officials have announced plans to categorize xylazine as a class C drug, with severe penalties for those involved in its distribution. This decision comes in light of the urgent need to safeguard the public from the dangers associated with these substances, underscoring the importance of comprehensive harm reduction strategies for individuals using drugs.